Developer docs
API playgroundTry for free, no card

Search company profiles

Neuralink

Full company profile

uuid0000073

Namestring
Neuralink
Legal namestring
Neuralink Corp.
Websiteurl
neuralink.com
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
brain-computer interfaces, neural implants, neurotechnology devices, implantable medical devices, neural signal decoding
Industry2 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Brain-Computer Interface / Implantable Neurotechnology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investigational device trials (pre-commercial)
TypeHardware Sales
Description

Neuralink is not yet generating commercial revenue: the N1 Implant is an investigational device deployed only under FDA-approved clinical trials (PRIME, CONVOY, CAN-PRIME, GB-PRIME, VOICE). Revenue model is currently nil/reverse-R&D; future revenue is expected to come from hardware sales of the implant, surgical robot procedure fees, and potentially recurring software/service revenue tied to decoder updates.

neuralink.com
Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Telepathy
Description

Neuralink's first product — the consumer-facing BCI capability that enables people with paralysis to directly control computers, phones, and robotic limbs using thoughts alone.

neuralink.com
+5 more records
Core offering1 text field

Neuralink develops and manufactures a fully implantable, wireless brain-computer interface platform consisting of the N1 Implant (Link) — a hermetically sealed device with 1,024+ electrodes across 64+ ultra-thin flexible threads — and the R1 surgical robot that inserts those threads into the cortex. Neural signals recorded by the implant are wirelessly transmitted to the Neuralink Application, which decodes them into digital commands enabling cursor, keyboard, and robotic-arm control (Telepathy), with investigational programs extending the platform to speech restoration (VOICE) and artificial vision (Blindsight). The device is currently provided only to participants enrolled in FDA/regulator-approved investigational clinical trials (PRIME, CONVOY, CAN-PRIME, GB-PRIME, VOICE).

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Neuralink's offering centers on a single integrated product platform for brain-computer interfaces (BCI), comprising the N1 Implant (also branded "Link") as the core implantable device, the R1 Robot that surgically inserts its electrode threads, the N1 Charger that powers it inductively, and the Neuralink Application that decodes neural signals into digital commands. Around this hardware platform sit a portfolio of clinical-trial products and capability modules: the flagship "Telepathy" capability for cursor/keyboard/robotic-arm control, the investigational Blindsight vision-restoration program, and the VOICE speech-restoration study, each backed by named trials (PRIME, CONVOY, CAN-PRIME, GB-PRIME). Complementing the BCI product is the open-source datarepo platform for managing the multimodal neuroscience data generated across Neuralink's vertically integrated R&D, manufacturing, surgery, and clinical operations, and the Neuralink Patient Registry service that recruits and pre-screens participants for trials.

Product and service13 records
1N1 Implant (Link)
CategoryCore product — implantable brain-computer interface
Description

A fully implantable, cosmetically invisible, wireless brain-computer interface the size of a U.S. quarter. It records neural activity through 1,024+ electrodes distributed across 64+ ultra-thin flexible threads (each thinner than a human hair), placed in the cortex by the R1 Robot; signals are processed by custom low-power chips and transmitted wirelessly to the Neuralink Application, which decodes them into digital commands.

2R1 Robot (Surgical Robot)
CategoryCore product — surgical robot
Description

A neurosurgical robot designed to insert the N1 Implant's electrode threads into the cortex. It features a base structure with 3-axis linear motion, a robot head containing 5 camera systems and OCT optics, and a needle thinner than a human hair that grasps, inserts, and releases threads while avoiding blood vessels. Operated under the oversight of board-certified neurosurgeons.

3N1 Charger
CategoryCore product — accessory
Description

A compact inductive charger that wirelessly charges the N1 Implant's onboard battery from outside the body, enabling hermetic sealing and cosmetic invisibility without physical connectors.

4Neuralink Application
CategoryCore product — companion software
Description

Companion software application that receives wirelessly transmitted neural data from the N1 Implant, decodes the data stream into actions and intents (cursor movements, clicks, text), and runs on external devices such as computers.

5Telepathy
CategoryProduct capability — motor control
Description

Neuralink's first product name for the cursor/keyboard/robotic-arm control capability enabled by the N1 Implant. Telepathy records neural activity from brain regions responsible for the muscles of the hands and arms and translates those signals into digital commands, bypassing damaged neural pathways to enable people with paralysis to directly control computers, phones, and robotic limbs using their thoughts alone.

6Blindsight
CategoryProduct program — vision restoration
Description

Neuralink's vision-restoration program and upcoming clinical trial (received FDA Breakthrough Device Designation in September 2024). Designed to restore visual perception for people with severe vision impairment by using a camera on special glasses working in tandem with a brain implant that stimulates the visual cortex, initially providing low-resolution vision.

7VOICE Study (Speech Restoration)
CategoryClinical trial / product — speech restoration
Description

Investigational speech-restoration clinical trial (NCT07224256) using the N1 Implant, designed to help people with severe speech impairment from ALS, PLS, spinal cord injury, or stroke output verbal thought as text or directly to speech. ALS patients have used the BCI combined with generative AI voice cloning to produce audible speech that sounds like their original voice.

8PRIME Study
CategoryClinical trial
Description

Investigational medical device trial (NCT06429735) to evaluate the safety of the N1 Implant and R1 surgical robot, and assess the initial functionality of the BCI for enabling people with quadriplegia from spinal cord injury or ALS to control external devices with their thoughts. Active at Barrow Neurological Institute, University of Miami / The Miami Project to Cure Paralysis, University Health Network (Toronto Western Hospital), and Cleveland Clinic Abu Dhabi.

9CAN-PRIME Study
CategoryClinical trial
Description

Neuralink's first international clinical trial (NCT06700304), launched in Canada with Health Canada approval at University Health Network (Toronto Western Hospital). Investigates safety and initial BCI functionality in Canadian residents with quadriplegia due to ALS or cervical spinal cord injury.

10GB-PRIME Study
CategoryClinical trial
Description

Neuralink's first clinical study in Great Britain (launched July 2025), approved by MHRA, HRA/HCRW, and London–Camberwell St Giles REC. Conducted at University College London Hospitals NHS Foundation Trust and The Newcastle upon Tyne Hospitals NHS Foundation Trust; open to residents of Great Britain with limited or no ability to use both hands due to ALS, spinal cord injury, or other neurological conditions.

11CONVOY Study
CategoryClinical trial
Description

Feasibility trial (NCT06710626) launched November 2024 to extend BCI control using the N1 Implant to an investigational assistive robotic arm (Assistive Robotic Arm/ARA). Cross-enrolls participants from the PRIME Study; conducted at Barrow Neurological Institute with planned expansion to the University of Miami.

12datarepo
CategoryOpen-source data platform
Description

Open-source platform for managing multimodal data, including real-time neural signals, histopathology images, manufacturing data, surgery video, and 3D volumetric brain scans. The datarepo catalog is a Python library that declaratively defines data sources as code, federates disparate data sources (Delta Lake, Parquet, virtual tables), generates a static web UI, and produces a stateless ROAPI configuration.

13Neuralink Patient Registry
CategoryService — clinical trial recruitment
Description

Online registry through which individuals with conditions such as quadriplegia, paraplegia, vision loss, hearing loss, aphasia, or amputation can register to learn about current and future Neuralink clinical trials. Open in the United States and Canada; preliminary eligibility assessment only — enrollment in a trial requires separate consent.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Non-invasive EEG-based BCI developer commercializing consumer and education-focused brain-signal products; represents the non-invasive competitive threat and consumer-tier category adjacent to Neuralink's implantable focus.

TypeDirect peer
Description

Direct competitor developing an endovascular (stent-based) brain-computer interface that avoids open brain surgery and has secured FDA IDE approval. Targets similar paralysis/ALS patient populations as Neuralink's Telepathy program.

TypeBroad incumbent
Description

Broad incumbent with significant neuromodulation and DBS franchises plus active BCI-adjacent R&D; competes for hospital-neurosurgery wallet share and is a potential partner or acquirer of BCI IP.

TypeBroad incumbent
Description

Broad incumbent via its St. Jude / Abbott Neuromodulation business (DBS, SCS, DRG), with established neurosurgical sales channels and FDA-approved implantable neurostimulators that compete for the same hospital budgets and OR slots.

TypeDirect peer
Description

Direct competitor developing a thin-film cortical-surface electrode array (Layer 7) aimed at higher-resolution neural recording with a less invasive surgical footprint than penetrating electrodes.

TypeDirect peer
Description

Direct competitor building high-bandwidth intracortical BCI technology targeting both medical (communication/motor restoration) and future consumer applications — closely aligned with Neuralink's neural-data-rate roadmap.

TypeEmerging player
Description

Early-stage minimally invasive BCI developer focused on brain-stimulation psychiatric applications; adjacent category participant in the implantable-neuromodulation space alongside Neuralink.

TypeDirect peer
Description

Direct competitor with the longest track record in intracortical BCI using Utah-array microelectrodes; competing for the same motor-restoration and communication applications as Neuralink, including FDA Breakthrough-aligned programs.

TypeBroad incumbent
Description

Established medtech incumbent with deep neuromodulation franchises (DBS, SCS, VNS, PNS) and global neurosurgical commercial infrastructure — the most likely strategic acquirer or competitor as Neuralink moves toward commercialization.

10Science Corp.
TypeEmerging player
Description

Founded by Neuralink co-founder Max Hodak; developing BCI and sensory-prosthetic technologies including a Prima retinal prosthesis that has restored sight to >40 blind patients — overlapping in vision-restoration and neural-interface IP.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability12 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors45 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neuralink

Brain-Computer Interface / Implantable Neurotechnologyneuralink.com

Neuralink firmographics

Firmographics
Name
Neuralink
Legal name
Neuralink Corp.
Website
https://neuralink.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

Neuralink industry classification

Industry
Product category
Brain-Computer Interface / Implantable Neurotechnology
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Brain-computer interfaces
  • Neural implants
  • Neurotechnology devices
  • Implantable medical devices
  • Neural signal decoding

Where Neuralink is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Markets served

Neuralink business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure

Revenue model

  1. Investigational device trials (pre-commercial): Neuralink is not yet generating commercial revenue: the N1 Implant is an investigational device deployed only under FDA-approved clinical trials (PRIME, CONVOY, CAN-PRIME, GB-PRIME, VOICE). Revenue model is currently nil/reverse-R&D; future revenue is expected to come from hardware sales of the implant, surgical robot procedure fees, and potentially recurring software/service revenue tied to decoder updates.

Go-to-market motion1 record

Neuralink product offering

Product offering

Core offering

Neuralink develops and manufactures a fully implantable, wireless brain-computer interface platform consisting of the N1 Implant (Link) — a hermetically sealed device with 1,024+ electrodes across 64+ ultra-thin flexible threads — and the R1 surgical robot that inserts those threads into the cortex. Neural signals recorded by the implant are wirelessly transmitted to the Neuralink Application, which decodes them into digital commands enabling cursor, keyboard, and robotic-arm control (Telepathy), with investigational programs extending the platform to speech restoration (VOICE) and artificial vision (Blindsight). The device is currently provided only to participants enrolled in FDA/regulator-approved investigational clinical trials (PRIME, CONVOY, CAN-PRIME, GB-PRIME, VOICE).

Product overview

Neuralink's offering centers on a single integrated product platform for brain-computer interfaces (BCI), comprising the N1 Implant (also branded "Link") as the core implantable device, the R1 Robot that surgically inserts its electrode threads, the N1 Charger that powers it inductively, and the Neuralink Application that decodes neural signals into digital commands. Around this hardware platform sit a portfolio of clinical-trial products and capability modules: the flagship "Telepathy" capability for cursor/keyboard/robotic-arm control, the investigational Blindsight vision-restoration program, and the VOICE speech-restoration study, each backed by named trials (PRIME, CONVOY, CAN-PRIME, GB-PRIME). Complementing the BCI product is the open-source datarepo platform for managing the multimodal neuroscience data generated across Neuralink's vertically integrated R&D, manufacturing, surgery, and clinical operations, and the Neuralink Patient Registry service that recruits and pre-screens participants for trials.

Differentiator

Problem solved

Functional benefit

Brands

  • Telepathy: Neuralink's first product — the consumer-facing BCI capability that enables people with paralysis to directly control computers, phones, and robotic limbs using thoughts alone.
  • N1 Implant (Link)
  • R1 Robot
  • Blindsight
  • VOICE
  • datarepo

Products and services

  • N1 Implant (Link) A fully implantable, cosmetically invisible, wireless brain-computer interface the size of a U.S. quarter. It records neural activity through 1,024+ electrodes distributed across 64+ ultra-thin flexible threads (each thinner than a human hair), placed in the cortex by the R1 Robot; signals are processed by custom low-power chips and transmitted wirelessly to the Neuralink Application, which decodes them into digital commands.
  • R1 Robot (Surgical Robot) A neurosurgical robot designed to insert the N1 Implant's electrode threads into the cortex. It features a base structure with 3-axis linear motion, a robot head containing 5 camera systems and OCT optics, and a needle thinner than a human hair that grasps, inserts, and releases threads while avoiding blood vessels. Operated under the oversight of board-certified neurosurgeons.
  • N1 Charger A compact inductive charger that wirelessly charges the N1 Implant's onboard battery from outside the body, enabling hermetic sealing and cosmetic invisibility without physical connectors.
  • Neuralink Application Companion software application that receives wirelessly transmitted neural data from the N1 Implant, decodes the data stream into actions and intents (cursor movements, clicks, text), and runs on external devices such as computers.
  • Telepathy Neuralink's first product name for the cursor/keyboard/robotic-arm control capability enabled by the N1 Implant. Telepathy records neural activity from brain regions responsible for the muscles of the hands and arms and translates those signals into digital commands, bypassing damaged neural pathways to enable people with paralysis to directly control computers, phones, and robotic limbs using their thoughts alone.
  • Blindsight Neuralink's vision-restoration program and upcoming clinical trial (received FDA Breakthrough Device Designation in September 2024). Designed to restore visual perception for people with severe vision impairment by using a camera on special glasses working in tandem with a brain implant that stimulates the visual cortex, initially providing low-resolution vision.
  • VOICE Study (Speech Restoration) Investigational speech-restoration clinical trial (NCT07224256) using the N1 Implant, designed to help people with severe speech impairment from ALS, PLS, spinal cord injury, or stroke output verbal thought as text or directly to speech. ALS patients have used the BCI combined with generative AI voice cloning to produce audible speech that sounds like their original voice.
  • PRIME Study Investigational medical device trial (NCT06429735) to evaluate the safety of the N1 Implant and R1 surgical robot, and assess the initial functionality of the BCI for enabling people with quadriplegia from spinal cord injury or ALS to control external devices with their thoughts. Active at Barrow Neurological Institute, University of Miami / The Miami Project to Cure Paralysis, University Health Network (Toronto Western Hospital), and Cleveland Clinic Abu Dhabi.
  • CAN-PRIME Study Neuralink's first international clinical trial (NCT06700304), launched in Canada with Health Canada approval at University Health Network (Toronto Western Hospital). Investigates safety and initial BCI functionality in Canadian residents with quadriplegia due to ALS or cervical spinal cord injury.
  • GB-PRIME Study Neuralink's first clinical study in Great Britain (launched July 2025), approved by MHRA, HRA/HCRW, and London–Camberwell St Giles REC. Conducted at University College London Hospitals NHS Foundation Trust and The Newcastle upon Tyne Hospitals NHS Foundation Trust; open to residents of Great Britain with limited or no ability to use both hands due to ALS, spinal cord injury, or other neurological conditions.
  • CONVOY Study Feasibility trial (NCT06710626) launched November 2024 to extend BCI control using the N1 Implant to an investigational assistive robotic arm (Assistive Robotic Arm/ARA). Cross-enrolls participants from the PRIME Study; conducted at Barrow Neurological Institute with planned expansion to the University of Miami.
  • datarepo Open-source platform for managing multimodal data, including real-time neural signals, histopathology images, manufacturing data, surgery video, and 3D volumetric brain scans. The datarepo catalog is a Python library that declaratively defines data sources as code, federates disparate data sources (Delta Lake, Parquet, virtual tables), generates a static web UI, and produces a stateless ROAPI configuration.
  • Neuralink Patient Registry Online registry through which individuals with conditions such as quadriplegia, paraplegia, vision loss, hearing loss, aphasia, or amputation can register to learn about current and future Neuralink clinical trials. Open in the United States and Canada; preliminary eligibility assessment only — enrollment in a trial requires separate consent.

Companies that use Neuralink

Customer profile

Ideal customer profiles2 records

Neuralink technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability12 records

Feature8 records

Neuralink partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights7 records

Neuralink competitors and assessment

Company assessment

Emerging players

  • BrainCo: Non-invasive EEG-based BCI developer commercializing consumer and education-focused brain-signal products; represents the non-invasive competitive threat and consumer-tier category adjacent to Neuralink's implantable focus.
  • Motif Neurotech: Early-stage minimally invasive BCI developer focused on brain-stimulation psychiatric applications; adjacent category participant in the implantable-neuromodulation space alongside Neuralink.
  • Science Corp. Founded by Neuralink co-founder Max Hodak; developing BCI and sensory-prosthetic technologies including a Prima retinal prosthesis that has restored sight to >40 blind patients — overlapping in vision-restoration and neural-interface IP.

Direct peers

  • Synchron: Direct competitor developing an endovascular (stent-based) brain-computer interface that avoids open brain surgery and has secured FDA IDE approval. Targets similar paralysis/ALS patient populations as Neuralink's Telepathy program.
  • Precision Neuroscience: Direct competitor developing a thin-film cortical-surface electrode array (Layer 7) aimed at higher-resolution neural recording with a less invasive surgical footprint than penetrating electrodes.
  • Paradromics: Direct competitor building high-bandwidth intracortical BCI technology targeting both medical (communication/motor restoration) and future consumer applications — closely aligned with Neuralink's neural-data-rate roadmap.
  • Blackrock Neurotech: Direct competitor with the longest track record in intracortical BCI using Utah-array microelectrodes; competing for the same motor-restoration and communication applications as Neuralink, including FDA Breakthrough-aligned programs.

Broad incumbents

  • Boston Scientific: Broad incumbent with significant neuromodulation and DBS franchises plus active BCI-adjacent R&D; competes for hospital-neurosurgery wallet share and is a potential partner or acquirer of BCI IP.
  • Abbott: Broad incumbent via its St. Jude / Abbott Neuromodulation business (DBS, SCS, DRG), with established neurosurgical sales channels and FDA-approved implantable neurostimulators that compete for the same hospital budgets and OR slots.
  • Medtronic: Established medtech incumbent with deep neuromodulation franchises (DBS, SCS, VNS, PNS) and global neurosurgical commercial infrastructure — the most likely strategic acquirer or competitor as Neuralink moves toward commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Neuralink social profiles

Digital presence

Neuralink compliance and trust

Trust signal

Compliance7 records

Neuralink financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neuralink leadership team

Management profile

Number of profiles

Profiles4 records

Neuralink funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors45 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neuralink M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuralink

What does Neuralink do?

Neuralink develops and manufactures a fully implantable, wireless brain-computer interface platform consisting of the N1 Implant (Link) — a hermetically sealed device with 1,024+ electrodes across 64+ ultra-thin flexible threads — and the R1 surgical robot that inserts those threads into the cortex. Neural signals recorded by the implant are wirelessly transmitted to the Neuralink Application, which decodes them into digital commands enabling cursor, keyboard, and robotic-arm control (Telepathy), with investigational programs extending the platform to speech restoration (VOICE) and artificial vision (Blindsight). The device is currently provided only to participants enrolled in FDA/regulator-approved investigational clinical trials (PRIME, CONVOY, CAN-PRIME, GB-PRIME, VOICE).

Is Neuralink a public or private company?

Neuralink is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neuralink founded?

Neuralink was founded in 2016. It employs 501 to 1,000 people.

Where is Neuralink based?

Neuralink is headquartered in Austin, United States, in the North America region.

How does Neuralink make money?

One revenue line is on record: investigational device trials (pre-commercial).

Who are Neuralink's main competitors?

Emerging players on record are BrainCo, Motif Neurotech and Science Corp.. Direct peers are Synchron, Precision Neuroscience, Paradromics and Blackrock Neurotech. Broad incumbents are Boston Scientific, Abbott and Medtronic.

Does Neuralink have an API?

No public API is recorded for Neuralink.

What industry is Neuralink in?

Neuralink's product category is Brain-Computer Interface / Implantable Neurotechnology. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Naver‘AI를 아예 뇌에 심어버려?’ 통제불가…“시험의 시대 끝났다”AI cheating in national professional exams has raised concerns about fairness, with experts warning that brain-computer interfaces could make traditional studying and testing obsolete. UNESCO and OECD recommend shifting to critical thinking, creativity, and ethical judgment as key skills. The article notes ongoing research into brain-computer interfaces, including Neuralink's first clinical participant.iPhone in CanadaEdmonton Man Uses His Thoughts to Create Music Video With NeuralinkKenneth Shock, an ALS patient with a Neuralink implant, directed a music video for the song 'ALLOW ALWAYS' using AI tools, completing it in four to five days for $200 CAD. The video features a character named Claudia, with lyrics written by Claude Opus and lip-synced footage from MiniMax H3 Max. Shock is already working on another video, 'Two-Step Verification,' teased for November 19.IfengWhy did Huang Renxun step down directly after cheating, while Musk has had four children and nothing happened?Nvidia founder Jensen Huang resigned as CEO and board member on November 12 after admitting infidelity with an executive, a second affair with a subordinate, and a board investigation. The article contrasts this with Elon Musk's four children with a Neuralink executive, noting Musk's dual-class share structure limits board oversight.StartupHub.aiNeuralink spent 72 hours killing the button pressNeuralink spent 72 hours in a participant's home testing hands-free voice dictation, aiming to eliminate button presses between thought and speech. The study integrated BCI dictation into iOS apps and lock-screen status, but decoders still err and the device remains investigational without FDA approval.Tom's HardwareElon Musk says Neuralink is ready to cure blindness — says Blindsight will ‘enable even those who are completely blind or have never seen to see’Elon Musk said Neuralink's second product, Blindsight, is ready from an engineering standpoint and waiting for regulatory approval. The device aims to enable people who are completely blind or have never seen to see by converting camera images into brain signals. Musk also noted the company's first product, Telepathy, enables high-speed communication by thinking.NewsBytesTelepathy, Blindsight: Musk announces Neuralink implants targeting communication and visionElon Musk announced Neuralink's first two commercial products, Telepathy and Blindsight, targeting communication and vision restoration. Telepathy enables high-speed thought-based communication, while Blindsight aims to restore functional sight to the blind, with the latter ready for regulatory approval.The Times of IndiaElon Musk reveals names of first two products that his neurotechnology company Neuralink will launchElon Musk revealed the first two Neuralink products, Telepathy and Blindsight, with Telepathy enabling thought-based communication and Blindsight restoring vision. The company is awaiting regulatory approval for Blindsight. A 72-hour hackathon tested five software and hardware integrations.Nate"생각만으로 컴퓨터 조작한다"…뇌·컴퓨터 잇는 BCI 기술의 미래 : 네이트 뉴스Yonsei University professor Lim Chang-hwan explained BCI technology on EBS, noting that brainwave signals from imagined movements are needed to control devices. He said only about 10% of people can do this without training, and high-level cognitive signals remain hard to decode. Neuralink demonstrated BCI-controlled robot arms in October 2025.CNBCTV18Neuralink Telepathy: Elon Musk says thought-based communication could outpace speech and typing - CNBC TV18Elon Musk said Neuralink's Telepathy product will enable thought-based communication with bandwidth exceeding speech or typing speeds within a few years. The company's October 29 engineering sprint added automatic speech detection, AI agent activation, and iOS keyboard integration. Musk also expressed hope for future motor-signal routing to restore limb movement.BeincryptoElon Musk Is Selling a Telepathic Future: Can You Invest Before IPO?Elon Musk shared new Neuralink brain-chip demos on Oct 30, including a thought-controlled Grok agent and speech sent into iPhone calls. The company, valued at $9 billion, remains private, so most retail investors outside the US have no regulated way to invest, with pre-IPO tokens like PreStocks carrying high risk and no shareholder rights.